Age Criteria for RAI Treatment in Thyrotoxicosis
RAI therapy should be avoided in children under 5 years of age, is acceptable between ages 5-10 years if the administered activity is <10 mCi, and is acceptable above age 10 if the activity is >150 μCi/g of thyroid tissue. 1
Pediatric Age-Specific Guidelines
Children Under 5 Years
- RAI is contraindicated due to heightened tissue sensitivity to radiation 2
- Surgery is the preferred definitive treatment if radical therapy is required 2
- Methimazole remains first-line therapy for initial management 1
Children 5-10 Years
- RAI is acceptable with strict dosing limits: administered activity must be <10 mCi 1
- This age group represents a transition zone where careful risk-benefit assessment is essential
- The restriction reflects concerns about radiation exposure during critical developmental periods
Children Over 10 Years
- RAI is acceptable when activity exceeds 150 μCi/g of thyroid tissue 1
- This threshold ensures adequate ablative effect while accounting for the child's thyroid size
- Treatment approach becomes more similar to adult protocols
Clinical Decision Algorithm
When to Consider RAI in Pediatric Patients:
- Contraindication to antithyroid drugs (e.g., severe adverse reactions)
- Poor compliance with medical therapy
- Relapse after prolonged medical treatment (typically after 1-2 years of methimazole)
- Family/patient preference for definitive therapy 2
When Surgery is Preferred Over RAI:
- Child is too young for RAI (<5 years)
- Very large goiter present
- High-volume thyroid surgeon available with pediatric experience 1
Adult Considerations
In adults, there are no upper age restrictions for RAI therapy. However, special precautions apply:
Elderly Patients
- Should receive beta-blockade prior to RAI if they have symptomatic thyrotoxicosis, cardiovascular disease, or severe hyperthyroidism 1
- Consider methimazole pretreatment in those at increased risk for complications from worsening hyperthyroidism 1
- Elderly patients with toxic multinodular goiter or toxic adenoma warrant particular attention to pre-treatment stabilization 1
High-Risk Adult Patients
Pretreatment optimization is essential for patients with:
- Resting heart rate >90 bpm
- Cardiovascular disease
- Free T4 levels 2-3 times upper limit of normal
- Significant comorbidities (renal failure, poorly controlled diabetes, cerebrovascular disease) 1
Absolute Contraindications (All Ages)
RAI is absolutely contraindicated in:
- Pregnancy 1
- Lactation 1
- Coexisting thyroid cancer 1
- Inability to comply with radiation safety guidelines 1
- Females planning pregnancy within 4-6 months 1
A pregnancy test must be obtained within 48 hours prior to RAI administration in all females of childbearing potential 1
Critical Pitfalls to Avoid
Do not use RAI in very young children (<5 years) even with parental pressure—the radiation sensitivity risk is too high 2
Do not skip beta-blockade in elderly patients before RAI, as post-treatment thyroid hormone release can precipitate cardiac complications 1
Do not assume all children need immediate RAI after antithyroid drug failure—methimazole can be continued until the child reaches an appropriate age for definitive therapy 1
Do not overlook the option of surgery in young children when RAI is contraindicated, provided a high-volume thyroid surgeon is available 1
Nuances in Pediatric Practice
The 2011 ATA/AACE guidelines acknowledge that exceptional circumstances may warrant RAI in very young children, such as when a child develops severe reactions to antithyroid drugs and surgical expertise is unavailable 1. However, this should be considered only as a last resort.
European practice (reflected in the 2018 French guidelines) tends to be more conservative, often delaying RAI until after puberty, while North American practice may offer RAI earlier after 1-2 years of medical treatment 2. The evidence base for long-term cancer risk in prepubertal children remains limited, though available data from 36-year follow-up studies have not shown increased cancer risk 2.
The goal of RAI therapy should always be to render the patient hypothyroid (not euthyroid), as this minimizes the risk of persistent hyperthyroidism and, theoretically, secondary thyroid malignancy 2. This is particularly important in pediatric patients given their longer life expectancy and cumulative radiation exposure considerations.